Amrutanjan Health Care credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
−36.4−36.4−83.2−26.6−75.5
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−0.10×−0.10×−0.25×−0.09×−0.26×
−0.50×−0.48×−1.43×−0.52×−1.70×
355.72×355.72×235.74×288.20×508.18×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

AMRUTANJAN₹493.20

Amrutanjan Health Care Limited

· Pharma & Health
₹ CrorePeersJAGSNPHARMNGLFINESIGACHILINCOLNSYNCOMFTHEMISMEDHESTERBIOMcap ₹1,426 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Net Debt-75.5-26.6-83.2-36.4-36.4
Net Debt/Equity-0.26-0.09-0.25-0.10-0.10
Net Debt/EBITDA-1.70-0.52-1.43-0.48-0.50
Interest Coverage (EBIT/Interest)508.18288.20235.74355.72355.72
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.